hit counter
Cara Therapeutics, Inc. (CARA) Stock News Sentiment & Price - Sentifly
CARA - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cara Therapeutics, Inc. (CARA)

USA
Biotechnology
NASDAQ
CARA Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CARA Latest news
GlobeNewsWire
Neutral
Cara Therapeutics to Present at Upcoming Investor Conferences
2021-11-09 16:30

STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, President and Chief Executive Officer, will participate in the following upcoming investor conferences in November:

Seeking Alpha
Neutral
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript
2021-11-08 20:52

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
2021-11-08 18:23

Cara (CARA) delivered earnings and revenue surprises of 94.44% and 28.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Cara Therapeutics Reports Third Quarter 2021 Financial Results
2021-11-08 16:01

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) –

GlobeNewsWire
Neutral
Cara Therapeutics Announces CEO Transition
2021-11-03 08:00

Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

The Motley Fool
Neutral
3 Explosive Biotech Stocks -- Could They Shoot Even Higher?
2021-11-03 06:22

These biotech stocks have recently been responsible for a slew of rocketship emojis.

GlobeNewsWire
Neutral
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
2021-11-01 16:15

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 8, 2021 at 4:30 p.m. ET to report third quarter 2021 financial results and provide a corporate update.

Zacks Investment Research
Negative
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline
2021-11-01 16:06

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research
Negative
New Strong Sell Stocks for October 26th
2021-10-26 11:50

BJRI, CARA, BOOM, STNG, and UL have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2021.

GlobeNewsWire
Neutral
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
2021-10-04 07:00

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from the KARE Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. Results were presented by Brian Kim, MD, Associate Professor of Dermatology and Co-Director of the Center for the Study of Itch and Sensory Disorders at Washington University School of Medicine, during the Late Breaking News session of the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 2, 2021.

Loading more news...